Carregant...
Exome sequencing covers >98% of mutations identified on targeted next generation sequencing panels
BACKGROUND: With the expanded availability of next generation sequencing (NGS)-based clinical genetic tests, clinicians seeking to test patients with Mendelian diseases must weigh the superior coverage of targeted gene panels with the greater number of genes included in whole exome sequencing (WES)...
Guardat en:
| Publicat a: | PLoS One |
|---|---|
| Autors principals: | , , , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Public Library of Science
2017
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5289469/ https://ncbi.nlm.nih.gov/pubmed/28152038 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0170843 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|